
|Videos|June 19, 2018
Advancing Interest in Immune Checkpoint Blockade for GI Cancers
Author(s)Maria Svensson, MD
Maria Svensson, MD, Lund University, discusses the growing interest in checkpoint inhibitor blockade treatments for gastrointestinal cancers. In the past, there have been promising results with this treatment in metastatic disease.
Advertisement
Maria Svensson, MD, Lund University, discusses the growing interest in checkpoint inhibitor blockade treatments for gastrointestinal cancers. In the past, there have been promising results with this treatment in metastatic disease.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
The Targeted Pulse: FDA Approvals, Trial Updates, and ASH 2025 Previews
3
Odronextamab Plus CHOP Shows Promise in Early Phase 3 Data for Untreated DLBCL
4
Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL
5









































